Evidence map›Paper›PMID 40470252›Full record

ArticleResearch square2025

Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia.

Fanny Gonzales, Constanze Schneider, Gabriela Alexe, Shan Lin, Delan Khalid, Montserrat Alvarez, Allen Basanthakumar, Jana Ellegast, Lucy Merickel, Silvi Salhotra and 7 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Fanny GonzalesGeneva University Medical School.ORCID 0000-0003-1093-351X
Constanze SchneiderDana-Farber Cancer Institute.
Gabriela AlexeHarvard Medical School.ORCID 0000-0002-5668-6297
Shan LinSeattle Children's Research Institute.
Delan KhalidDana-Farber Cancer Institute.
Montserrat AlvarezGeneva University Medical School.
Allen BasanthakumarDana-Farber Cancer Institute.ORCID 0000-0001-7664-5030
Jana EllegastUniversity of Zurich.
Lucy MerickelDana-Farber Cancer Institute.
Silvi SalhotraDana-Farber Cancer Institute.
Audrey TaillonDana-Farber Cancer Institute.
Mark WunderlichCincinnati Children's Hospital Medical Center.
Marc AnsariUniversity Hospital of Geneva.
Jennifer PerryDana-Farber Cancer Institute.
Barbara DegarDana-Farber Cancer Institute.
Yana PikmanDana-Farber Cancer Institute.ORCID 0000-0002-5336-0216
Kimberly StegmaierDana-Farber Cancer Institute.ORCID 0000-0003-0218-7895

Funding

Targeting Pediatric Cancer VulnerabilitiesR35CA283977 · NCI · DANA-FARBER CANCER INST · PI Kimberly Stegmaier · 2023 to 2026
$4.2M
Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemiaR00CA263161 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI Shan Lin · 2024 to 2026
$747k
NCI NIH HHS R00 CA263161NCI NIH HHS R35 CA283977
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40470252
PMCPMC12136236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.